Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials.

"Disclosure statement : I.P. has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, Otsuka Pharmaceutical and F. Hoffmann-La Roche AG. The authors declare no other conflicts of interest."

"Funding This work was supported by grants from the Swedish Rheumatism Association (R-941095 to I.P. and R-939149 to C.S.); King Gustaf V’s 80-year Foundation (FAI-2020–0741 to I.P. and FAI-2020–0663 to C.S.); Professor Nanna Svartz Foundation (2020–00368); Swedish Society of Medicine (SLS-974449); Nyckelfonden (OLL-974804); Ulla and Roland Gustafsson Foundation (2021–26); Region Östergötland (ALF Grants; RÖ-932055); Region Stockholm (FoUI-955483); and Karolinska Institutet. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. Disclosure statement: I.P. has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, Otsuka Pharmaceutical and F. Hoffmann-La Roche AG. The authors declare no other conflicts of interest."